Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herzuma and pertuzumab in early HER2-positive breast cancer
NCT06907082Completed
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Dec 2020
- Primary completion
- Mar 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of trastuzumab in breast cancer, sponsored by Fundación para la Formación e Investigación Sanitaria. Primary endpoint: Pathological Complete Response at 18 months. Started Dec 2020; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06907082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06907082.